Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Acquired Generalized Lipodystrophy (Lawrence Syndrome). According to GlobalData, Phase II drugs for Acquired Generalized Lipodystrophy (Lawrence Syndrome) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mibavademab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mibavademab is under development for the treatment of congenital or acquired generalized lipodystrophy and obesity. The drug candidate is administered through intravenous and subcutaneous routes. It acts by targeting the leptin receptor (LEPR). The drug candidate is developed based on velocimmune platform technology.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Mibavademab’s drug-specific PTSR and LoA scores, buy the report here.